EHA 2015 | SABRINA trial: Subcutaneous versus intravenous rituximab for follicular lymphoma
Andrew Davies
Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the University of Southampton, Southampton, UK, discusses the update of the phase 3 SABRINA trial that was presented at the 20th Congress of the European Hematology Association (EHA). SABRINA evaluated subcutaneous versus intravenous rituximab in patients with previously untreated follicular lymphoma.
Related videos
1:53
Oral azacitidine plus R-CHOP for previously untreated NHL
John Leonard
2:05
AUGMENT-ing treatment: lenalidomide plus rituximab for R/R indolent NHL
John Leonard
Reversible BTK inhibitor ARQ 531 for CLL and NHL
Jennifer Woyach
1:21
Bispecific mosunetuzumab shows promise in R/R follicular lymphoma and DLBCL
Ian Flinn
3:11
CD47-targeting antibody: targeting the source of non-Hodgkin lymphoma
Irving Weissman
